Europe Blood Screening Market, By Products and Services (Reagents and Kits, Instruments, Software and Services), Technology (Nucleic Acid Test, Enzyme-Linked Immunosorbent Assay, Rapid Tests, Western Blot Assay, Next-Generation Sequencing, Others), Disease Type (Respiratory Diseases, Diabetes Mellitus, Oncology, Cholesterol, HIV/AIDS, Cold and Flu, Infectious Diseases, Others), End User (Diagnostic Centers, Blood Bank, Hospitals, Clinics, Ambulatory Surgical Centers), Country (Germany, United Kingdom, Italy, France, Russia, Switzerland, Netherlands, Spain, Turkey, Belgium and Rest of Europe) Industry Trends and Forecast to 2029.
Market Analysis and Insights : Europe Blood Screening Market
Data Bridge Market Research analyses that the Europe blood screening market to be grow at a CAGR of 9.00% in the forecast period of 2022-2029.
Blood screening is a medical process that checks for the presence or absence of HBV, HIV, HCV, syphilis, malaria, and other infectious diseases in donated blood. To reduce the danger of transfusion-transmitted infections, donated blood is checked for certain infectious disorders (TTIs).
One of the major reasons likely to boost the growth and demand of the blood screening market is the emergence of new pathogens. The rise in the blood donations as well as blood donors and technological improvements in healthcare sector are expected to propel the global blood screening market forward. Similarly, the increase in the prevalence of infectious diseases is expected to boost market growth. Furthermore, the rising awareness about the safety of donated blood and growing geriatric population are projected to contribute to the market's growth. Other significant factors such as increase in the investment level for development of advanced technology and favourable government policies will cushion the growth rate of blood screening market.
Moreover, technical innovations and growth of healthcare sector are boosting plenty of beneficial opportunities that will propel the blood screening market forward over the projection period.
However, the lack of regulations for NAT in under developed countries and high costs associated with sampling of blood are expected to hinder the growth of the blood screening market. Major expenditure and operational cost of NAT devices are just a few of the challenges that could stymie the blood screening market's growth.
This Europe blood screening market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on Europe blood screening market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Europe Blood Screening Market Scope and Market Size
The Europe blood screening market is segmented on the basis of products and services, technology, disease type and end user. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.
- On the basis of products and services segment, the blood screening market is segmented into reagents and kits, instruments and software and services. Reagents and kits are further sub-segmented into NAT reagents and kits, ELISA reagents and kits others as well. NAT reagents is divided into enzymes and polymerases, standards and controls, probes and primers, buffers, nucleotides and solutions also labelling and detection reagents. ELISA reagents and kits is divided into immunosorbents, controls, conjugates (antigen or antibody-conjugated enzyme), substrates (of enzymes) also sample diluents and wash solutions. Instruments segment is further segmented into instruments, product types and instruments and purchase type.
- On the basis of technology, the blood screening market is segmented into nucleic acid test, enzyme-linked immunosorbent assay (ELISA), rapid tests, western blot assay, next-generation sequencing (NGS) and others. Nucleic acid test is further sub-segmented into transcription-mediated amplification (TMA) and real-time polymerase chain reaction (PCR). Enzyme-linked immunosorbent assay (ELISA) is further segmented into ELISA market, by platform, ELISA market, by generation. ELISA market, by platform is divided into chemiluminescence immunoassay (CLIA), fluorescence immunoassay (FIA) and colorimetric immunoassay (CI). ELISA market, by generation is divided into first-generation ELISA, second-generation ELISA, third-generation ELISA and fourth-generation and above.
- On the basis of disease type segment, the blood screening market is segmented into respiratory diseases, diabetes mellitus, oncology, cholesterol, HIV/AIDS, cold and flu, infectious diseases and others.
- The end user segment in the blood screening market is segmented into diagnostic centers, blood bank, hospitals, clinics and ambulatory surgical centers..
Europe Blood Screening Market Country Level Analysis
Europe blood screening market is analysed and market size insights and trends are provided by country, products and services, technology, disease type and end user as referenced above.
The countries covered in the Europe blood screening market report are Germany, United Kingdom, Italy, France, Russia, Switzerland, Netherlands, Spain, Turkey, Belgium and Rest of Europe.
Germany dominates the Europe blood screening market during the forecast period of 2022-2029 due to the presence of major key players, increasing awareness about blood donation and the availability of high-quality infrastructure for hospitals and clinical laboratories in this region.
The country section of the Europe blood screening market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
Europe blood screening market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for Europe blood screening market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the Europe blood screening market. The data is available for historic period 2010 to 2020.
Competitive Landscape and Europe Blood Screening Market Share Analysis
Europe blood screening market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, North America presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to Europe blood screening market.
Some of the major players operating in the Europe blood screening market are Enzo Biochem Inc., Meridian Bioscience, Inc., BD, Bio-Rad Laboratories, Inc., Thermo Fisher Scientific Inc., BioMérieux SA, Beckman Coulter, Inc., Abbott, F. Hoffmann-La Roche Ltd, Cepheid, GRIFOLS INTERNATIONAL, S.A., Siemens, Ortho Clinical Diagnostics, Immucor, Inc., Hologic Inc., DiaSorin, GFE, Trinity Biotech, Merck KGaA, among others.
SKU-